Author

Maria Pia Morelli

Observed names: M P Morelli, M Pia Morelli, M. P. Morelli, M. Pia Morelli, M.P. Morelli, Maria Morelli, Maria P Morelli, Maria P. Morelli

Institution: The University of Texas MD Anderson Cancer Center

Observed institutions: AstraZeneca (United Kingdom), National Institutes of Health, The University of Texas MD Anderson Cancer Center, University of Campania "Luigi Vanvitelli", University of Colorado Health, Spanish National Cancer Research Centre, National Heart, Lung, and Blood Institute, South Texas Accelerated Research Therapeutics, University of Colorado Cancer Center, National Cancer Institute, Center for Cancer Research, National Research Council, University of Colorado Anschutz, University of Naples Federico II, University of Colorado Denver

ORCID: 0009-0000-9543-6584

Observed ORCID: 0009-0000-9543-6584

OpenAlex ID: A5018825816

Characterizing the patterns of clonal selection in circulating tumor DNA from patients with colorectal cancer refractory to anti-EGFR treatment

2015 · M.P. Morelli, M.J. Overman, et al. · Annals of Oncology · 254

PDF

Survival improvement for patients with metastatic colorectal cancer over twenty years

2023 · Fadl A. Zeineddine, Mohammad A. Zeineddine, et al. · npj Precision Oncology · 188

PDF

PRMT1-mediated methylation of the EGF receptor regulates signaling and cetuximab response

2015 · Hsin-Wei Liao, Jung-Mao Hsu, et al. · Journal of Clinical Investigation · 155

PDF

Interaction between the epidermal growth factor receptor (EGFR) and the vascular endothelial growth factor (VEGF) pathways: a rational approach for multi-target anticancer therapy

2006 · F. Ciardiello, T. Troiani, et al. · Annals of Oncology · 125

PDF

Sequence-dependent antiproliferative effects of cytotoxic drugs and epidermal growth factor receptor inhibitors

2005 · M.P. Morelli, T. Cascone, et al. · Annals of Oncology · 111

Tremelimumab in Combination With Microwave Ablation in Patients With Refractory Biliary Tract Cancer

2018 · Changqing Xie, Austin G. Duffy, et al. · Hepatology · 101

Therapeutic Silencing of KRAS Using Systemically Delivered siRNAs

2014 · Chad V. Pecot, Sherry Y. Wu, et al. · Molecular Cancer Therapeutics · 95

PDF

Prioritizing Phase I Treatment Options Through Preclinical Testing on Personalized Tumorgraft

2011 · M. Pia Morelli, Emiliano Calvo, et al. · Journal of Clinical Oncology · 91

Association of blood biomarkers and autoimmunity with immune related adverse events in patients with cancer treated with immune checkpoint inhibitors

2021 · Despina Michailidou, Ali Raza Khaki, et al. · Scientific Reports · 90

PDF

Synergistic Antitumor Activity of Sorafenib in Combination with Epidermal Growth Factor Receptor Inhibitors in Colorectal and Lung Cancer Cells

2010 · Erika Martinelli, Teresa Troiani, et al. · Clinical Cancer Research · 89

Identification of Predictive Markers of Response to the MEK1/2 Inhibitor Selumetinib (AZD6244) in K- ras –Mutated Colorectal Cancer

2010 · John J. Tentler, Sujatha Nallapareddy, et al. · Molecular Cancer Therapeutics · 77

PDF

Phase I/II trial of encorafenib, cetuximab, and nivolumab in patients with microsatellite stable, BRAFV600E metastatic colorectal cancer.

2022 · Van K. Morris, Christine Megerdichian Parseghian, et al. · Journal of Clinical Oncology · 76

Modeling of Patient-Derived Xenografts in Colorectal Cancer

2017 · Anastasia Katsiampoura, Kanwal Raghav, et al. · Molecular Cancer Therapeutics · 64

PDF

Anti‐tumor activity of the combination of cetuximab, an anti‐EGFR blocking monoclonal antibody and ZD6474, an inhibitor of VEGFR and EGFR tyrosine kinases

2006 · Maria Pia Morelli, Tina Cascone, et al. · Journal of Cellular Physiology · 58

Clinicopathologic characteristics and gene expression analyses of non-KRAS 12/13, RAS-mutated metastatic colorectal cancer

2014 · V.K. Morris, F. A. San Lucas, et al. · Annals of Oncology · 55

PDF

Targeting vascular endothelial growth factor receptor-1 and -3 with cediranib (AZD2171): effects on migration and invasion of gastrointestinal cancer cell lines

2009 · M. Pia Morelli, Amy M. Brown, et al. · Molecular Cancer Therapeutics · 50

Preclinical Activity of the Rational Combination of Selumetinib (AZD6244) in Combination with Vorinostat in KRAS-Mutant Colorectal Cancer Models

2011 · M. Pia Morelli, John J. Tentler, et al. · Clinical Cancer Research · 47

PDF

A Pilot Study of the PD-1 Targeting Agent AMP-224 Used With Low-Dose Cyclophosphamide and Stereotactic Body Radiation Therapy in Patients With Metastatic Colorectal Cancer

2019 · Charalampos S. Floudas, Gagandeep Brar, et al. · Clinical Colorectal Cancer · 45

PDF

Combined immune checkpoint inhibition (ICI) with tremelimumab and durvalumab in patients with advanced hepatocellular carcinoma (HCC) or biliary tract carcinomas (BTC).

2019 · Charalampos S. Floudas, Changqing Xie, et al. · Journal of Clinical Oncology · 43

Synergistic activity of histone deacetylase and proteasome inhibition against pancreatic and hepatocellular cancer cell lines.

2011 · J L Spratlin, T M Pitts, et al. · PubMed · 43

Synergistic anti‐proliferative and pro‐apoptotic activity of combined therapy with bortezomib, a proteasome inhibitor, with anti‐epidermal growth factor receptor (EGFR) drugs in human cancer cells

2008 · Tina Cascone, Maria Pia Morelli, et al. · Journal of Cellular Physiology · 41

Molecular, Socioeconomic, and Clinical Factors Affecting Racial and Ethnic Disparities in Colorectal Cancer Survival

2024 · Mahmoud Yousef, Abdelrahman Yousef, et al. · JAMA Oncology · 35

PDF

Hurdles and Complexities of Codon 13KRASMutations

2012 · Maria Pia Morelli, Scott Kopetz · Journal of Clinical Oncology · 28

Small molecule epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in non-small cell lung cancer

2006 · T. Cascone, M.P. Morelli, et al. · Annals of Oncology · 28

Clinical utility of circulating cell-free DNA in advanced colorectal cancer

2017 · Allan A. Lima Pereira, Maria Pia Morelli, et al. · PLoS ONE · 25

PDF

Works count: 164

Citation count: 2,374

H-index: 25

I10-index: 38